scholarly journals ITIH4 acts as a protease inhibitor by a novel inhibitory mechanism

2021 ◽  
Vol 7 (2) ◽  
pp. eaba7381
Author(s):  
Rasmus Pihl ◽  
Rasmus K. Jensen ◽  
Emil C. Poulsen ◽  
Lisbeth Jensen ◽  
Annette G. Hansen ◽  
...  

Inter-α-inhibitor heavy chain 4 (ITIH4) is a poorly characterized plasma protein that is proteolytically processed in multiple pathological conditions. However, no biological function of ITIH4 has been identified. Here, we show that ITIH4 is cleaved by several human proteases within a protease-susceptible region, enabling ITIH4 to function as a protease inhibitor. This is exemplified by its inhibition of mannan-binding lectin–associated serine protease-1 (MASP-1), MASP-2, and plasma kallikrein, which are key proteases for intravascular host defense. Mechanistically, ITIH4 acts as bait that, upon cleavage, forms a noncovalent, inhibitory complex with the executing protease that depends on the ITIH4 von Willebrand factor A domain. ITIH4 inhibits the MASPs by sterically preventing larger protein substrates from accessing their active sites, which remain accessible and fully functional toward small substrates. Thus, we demonstrate that ITIH4 functions as a protease inhibitor by a previously undescribed inhibitory mechanism.

1997 ◽  
Vol 14 (6) ◽  
pp. 499-512 ◽  
Author(s):  
Paolo Perutelli ◽  
Paola Biglino ◽  
Pier Giorgio Mori

2009 ◽  
Vol 02 ◽  
pp. 13
Author(s):  
Caroline Cromwell ◽  
Louis M Aledort ◽  
Margaret Heisel Kurth ◽  
◽  
◽  
...  

The development of inhibitor antibodies that bind to active sites on the factor VIII (FVIII) molecule and neutralize its function and/or accelerate its clearance is the most serious adverse event and safety issue associated with the treatment of hemophilia A. Inhibitor development complicates hemostasis management and increases morbidity and the cost of treatment because bleeding episodes do not respond to standard replacement therapy. Risk factors for inhibitor development include genetic and non-genetic factors. Immunogenicity of the type of product used for replacement therapy may also play a role. Within the category of human-derived products, the presence of von Willebrand factor (vWF) bound to FVIII (vWF/FVIII products) may reduce its immunogenicity. The challenge for inhibitors is to reduce their incidence and, when present, to facilitate their eradication. Factor-bypassing agents have been used to treat acute bleeds in patients who have inhibitors. Immune tolerance induction (ITI) therapy is an alternative approach whose goal is to create tolerance to inhibitors and return patients to their native state. The use of ITI therapy has raised many questions, including the optimal regimen and cost. The basic science data on reduced immunogenicity of vWF/FVIII-containing products and their success in achieving ITI have given us an incentive to continue to explore this approach to both primary and secondary ITI.


2019 ◽  
Vol 11_2019 ◽  
pp. 74-81
Author(s):  
Bitsadze V.O. Bitsadze ◽  
Grigoryeva K.N. Grigoryeva ◽  
Ilalami I. Ilalami ◽  
Makatsariya A.D. Makatsariya ◽  
Mingalimov M.A. Mingalimov ◽  
...  

2019 ◽  
Vol 17 (7) ◽  
pp. 1018-1029 ◽  
Author(s):  
Soracha Ward ◽  
Jamie M. O'Sullivan ◽  
James S. O'Donnell

2021 ◽  
Vol 15 (1) ◽  
pp. 93-106
Author(s):  
K. N. Grigoreva ◽  
V. O. Bitsadze ◽  
J. Kh. Khizroeva ◽  
M. V. Tretyakova ◽  
D. A. Ponomarev ◽  
...  

ADAMTS-13 is a crucial metalloproteinase involved in liberating fragments of von Willebrand factor (vWF) into the plasma as well as regulating its activity by cleaving "ultra-large" multimers into smaller and less active counterparts. Many pathological conditions, including those emerged during pregnancy are characterized by increased level of vWF and decreased ADAMTS-13 activity. In this regard, it is necessary to monitor the levels of vWF and ADAMTS-13 activity to prevent thrombotic thrombocytopenic purpura (Moschcowitz disease) as one of the most severe forms of thrombotic microangiopathy. 


2007 ◽  
Vol 14 (3) ◽  
pp. 284-289 ◽  
Author(s):  
Evelyn Groot ◽  
Philip G de Groot ◽  
Rob Fijnheer ◽  
Peter J Lenting

Sign in / Sign up

Export Citation Format

Share Document